FDA Safety Announcement on the Importance of DPD Deficiency Discussions With Patients Before Capecitabine or 5FU Treatment

FDA Safety Announcement on the Importance of DPD Deficiency Discussions With Patients Before Capecitabine or 5FU Treatment

On January 24, the US Food and Drug Administration (FDA) released new information to increase awareness of recent updates to capecitabine and fluorouracil product labeling related to risks associated with dihydropyrimidine dehydrogenase deficiency.

For more information, read the FDA announcement.

Posted on 1/28/2025

Upcoming Events

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington